Search results
Results From The WOW.Com Content Network
The Monthly Index of Medical Specialities or MIMS is a pharmaceutical prescribing reference guide published in the United Kingdom since 1959 by Haymarket Media Group.MIMS is also published internationally by various organisations, including in Australia, New Zealand, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.
MIMS Ireland is used by the Irish Medicines Board to convey information on drug safety, [2] [3] and is a "recommended text" in the premises requirements for pharmacies issued by the Pharmaceutical Society of Ireland (PSI). [4] It is also listed as a reference for the use of drugs in sports by the Irish Sports Council. [5] [6]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Sacubitril/valsartan, sold under the brand name Entresto among others, is a fixed-dose combination medication for use in heart failure.It consists of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker valsartan.
Drug labelling, also referred to as prescription labelling, is a written, printed or graphic matter upon any drugs or any of its container, or accompanying such a drug. Drug labels seek to identify drug contents and to state specific instructions or warnings for administration, storage and disposal.
EMDEX drug information contents, arrangements, and therapeutic recommendations are supported by several references and clinical guidelines notably WHO Model Formulary, WHO ATC (Anatomical Therapeutic Chemical) Classification System, Nigeria's Essential Medicines List, and Standard Treatment Guidelines, etc. The information is regularly reviewed ...
[15] [16] Because the drug was the first GLP-1 agonist that could be taken once a day, sales projections in 2013 were €500M per year by 2018. [16] Sanofi resubmitted the application which the FDA accepted in September 2015, by which time Sanofi had lost the lead in the field of anti-diabetic drugs to Novo Nordisk. [17]
On the other hand, propyphenazone, a non-steroidal anti-inflammatory drug (NSAID), is proven to have a faster onset but shorter duration of action. [4] The combination of paracetamol and propyphenazone increases and prolongs the therapeutic activity of propyphenazone: peak blood plasma concentrations increase by about 40%, and the elimination ...